LYELLyell Immunopharma, Inc.同业对比
Lyell Immunopharma, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYEL本股 | $260M#8 | — | 1.1x#3 | 7229.0x#12 | -41.0%#11 | 20.0%#5 | -748344.4%#13 | -117.4%#10 | — | — | -14.3%#7 | — |
| VNDA | $305M#1 | — | 1.4x#5 | 1.4x#3 | 8.7%#7 | -1066.7%#16 | -70.0%#4 | -100.1%#9 | — | — | 14.9%#6 | — |
| UPB | $290M#2 | — | 1.1x#2 | 101.7x#10 | 20.4%#6 | -128.4%#13 | -5618.8%#11 | -52.9%#6 | — | — | -66.9%#10 | — |
| FULC | $288M#3 | — | 0.9x#1 | — | -100.0%#14 | -670.0%#15 | — | -24.1%#4 | — | — | -48.4%#9 | — |
| PYXS | $281M#4 | — | 24.5x#10 | 20.3x#8 | -14.2%#10 | -3.0%#7 | -609.2%#8 | -696.0%#12 | — | — | 52.3%#5 | — |
| CUE | $268M#6 | — | 116.1x#12 | 9.8x#6 | 195.7%#2 | 34.6%#3 | -96.7%#5 | -1151.6%#13 | — | — | 67.1%#2 | — |
| TRDA | $269M#5 | — | 1.2x#4 | 10.6x#7 | -87.9%#12 | -319.0%#14 | -621.1%#9 | -61.6%#7 | — | — | — | — |
| GLSI | $263M#7 | — | 84.3x#11 | — | — | -11.2%#8 | — | -621.1%#11 | — | — | — | — |
| CAMP | $254M#10 | — | — | 72.7x#9 | 436.5%#1 | -55.2%#11 | -1502.4%#10 | — | — | — | 56.1%#4 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#10 | -340.4%#7 | -42.9%#5 | -794.1%#2 | — | -46.8%#8 | — |
| MGNX | $260M#9 | — | 6.1x#8 | 1.7x#4 | -0.3%#9 | -11.4%#9 | -48.7%#3 | -0.2%#2 | — | — | 164.6%#1 | — |
| FHTX | $248M#11 | — | — | 8.0x#5 | 36.8%#5 | 14.2%#6 | -279.5%#6 | — | — | — | — | — |
| RNAC | $241M#13 | — | — | 603.6x#11 | -99.0%#13 | -68.3%#12 | -35851.3%#12 | — | — | — | — | — |
| AKBA | $241M#12 | — | 9.7x#9 | 1.0x#2 | 47.5%#4 | 92.4%#2 | 9.9%#1 | -21.2%#3 | — | — | — | — |
| ALXO | $241M#14 | — | 1.8x#7 | — | — | 24.6%#4 | — | -74.7%#8 | -84.4%#1 | — | 64.6%#3 | — |
| NATR | $232M#15 | 13.2x#1 | 1.7x#6 | 0.5x#1 | 5.7%#8 | 153.7%#1 | 5.2%#2 | 14.3%#1 | — | 9#1 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议